Novartis’s first-quarter sales and earnings beat consensus analyst estimates. So why did the company’s stock dip more than 2% first thing Thursday? The answer speaks to investors’ high expectations for its new CEO, Vas Narasimhan—and for his promise to focus
read moreThree of Takeda’s anticipated Shire buyout bids have already been rejected—and now, the Japanese drugmaker might just lose out to a competing bidder. Allergan, for instance, is already in talks for a buy. More: Allergan swoops in as Takeda's third
read moreNot even two months into a probe of officials accused of taking Novartis bribes, Greece’s parliament is handing off the investigation. More: Greek lawmakers hand off probe of politicians accused of taking Novartis bribes: report Source: fierce
read moreThe future may still be uncertain for AstraZeneca’s immuno-oncology therapy Imfinzi in first-line lung cancer. But the company has picked up an approval in that setting for fellow portfolio med Tagrisso, which targets tumors with a particular genetic mutation. More:
read moreTurns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s. Thursday, P&G said the two companies had inked a pact that will send Merck’s portfolio from Germany to Cincinnati, Ohio, for
read moreUS regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets. More: FDA clears first therapy for inherited rickets Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals